{Reference Type}: Journal Article
{Title}: Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer.
{Author}: Hendrixson M;Gladkiy Y;Thyagarajan A;Sahu RP;
{Journal}: Med Sci (Basel)
{Volume}: 12
{Issue}: 2
{Year}: 2024 Apr 7
暂无{DOI}: 10.3390/medsci12020020
{Abstract}: Lung cancer remains the leading cause of cancer-related deaths, with a poor prognosis. Of the two types, non-small cell lung cancer (NSCLC) is the major and most prevalent type and associated with low response rates to the current treatment options. Sorafenib, a multitargeted tyrosine kinase inhibitor used for various malignancies, gained attention for its potential efficacy in NSCLC. This review paper focuses on the findings of recent in vitro, in vivo, and clinical studies regarding the efficacy of sorafenib. Overall, sorafenib has shown definitive therapeutic potential in NSCLC cell lines, xenografts, and human subjects. Novel approaches to sorafenib delivery may improve its efficacy and should be the focus of further studies.